Sedat Suna/Getty Images News Novartis ( NVS ) said it will acquire U.S. biotech firm Excellergy for up to $2B in upfront and milestone payments, in a move to strengthen its allergy portfolio. The deal, which is expected to close in the second half of the year, will add Excellergy's drug candidate that's currently in early-stage trials to Novartis' ( NVS ) portfolio. The drug, called Exl-111, is a ...
Sedat Suna/Getty Images News Novartis ( NVS ) said it will acquire U.S. biotech firm Excellergy for up to $2B in upfront and milestone payments, in a move to strengthen its allergy portfolio. The deal, which is expected to close in the second half of the year, will add Excellergy's drug candidate that's currently in early-stage trials to Novartis' ( NVS ) portfolio. The drug, called Exl-111, is a trifunctional Effector Cell Response Inhibitor designed to treat certain allergic disorders. If confirmed clinically, Exl-111's mechanism could support earlier symptom relief, stronger disease control, more convenient dosing and broader use across food allergy, allergic asthma and other IgE-driven diseases. "Excellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data," said Fiona Marshall, president of Biomedical Research, Novartis ( NVS ). "Together, we will be ideally positioned to realize the full potential of Exl-111 and the broader ECRI pipeline for the millions of patients living with severe, debilitating allergic diseases," said Excellergy CEO Todd Zavodnick. More on Novartis Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth Novartis (NVS) Shareholder/Analyst Call Prepared Remarks Transcript Novartis to buy experimental breast cancer drug for up to $3B
Piece by late South African artist Dumile Feni is part of new series History Doesn’t Repeat Itself, But It Does Rhyme On the second floor of the Reina Sofía, in the very spot where Picasso’s Guernica was first exhibited when it arrived in the Madrid museum 34 years ago, there now hangs a smaller, near-namesake of the Spanish artist’s most famous work. While African Guernica, which was drawn by the...
Piece by late South African artist Dumile Feni is part of new series History Doesn’t Repeat Itself, But It Does Rhyme On the second floor of the Reina Sofía, in the very spot where Picasso’s Guernica was first exhibited when it arrived in the Madrid museum 34 years ago, there now hangs a smaller, near-namesake of the Spanish artist’s most famous work. While African Guernica, which was drawn by the late South African artist Dumile Feni in 1967, may lack the scale of Picasso’s masterpiece, its depth, anger and unnerving juxtaposition of man and beast, light and dark, and innocence and cruelty, are every bit as disturbing. Continue reading...
(RTTNews) - TravelSky Technology Ltd. (TSYHF, TSYHY, 0696.HK), an IT solutions provider for China's air travel and tourist industry, reported higher profit in fiscal 2025, but revenues were lower than last year.
(RTTNews) - TravelSky Technology Ltd. (TSYHF, TSYHY, 0696.HK), an IT solutions provider for China's air travel and tourist industry, reported higher profit in fiscal 2025, but revenues were lower than last year.
BrendanHunter/E+ via Getty Images Investment Thesis In the three months since my last publication , Canada Natural Resources Limited ( CNQ ) has seen its market value rise by 44%. But that doesn't make the company overbought or overvalued in the slightest, and I'm sticking with my top-tier "Strong Buy" rating. Given the continuing escalation in the Middle East, prices for energy resources remain a...
BrendanHunter/E+ via Getty Images Investment Thesis In the three months since my last publication , Canada Natural Resources Limited ( CNQ ) has seen its market value rise by 44%. But that doesn't make the company overbought or overvalued in the slightest, and I'm sticking with my top-tier "Strong Buy" rating. Given the continuing escalation in the Middle East, prices for energy resources remain abnormally high, thereby increasing the potential profits of companies in the E&P segment. It is CNQ, in particular, a broadly diversified company whose asset portfolio includes both the extraction and production of energy resources and their transportation. If we add to this the fact that more than a third of the company's sales come from exports to foreign markets, it is clear that the current crisis in the global energy market only increases CNQ's appeal to investors betting on price appreciation. I want to discuss four key factors in this article that keep my confidence in CNQ at its highest, and make it the top pick among the energy assets in my portfolio. These are influenced by both the current geopolitical landscape and the company's latest financial results. Factor #1: The Impact of the "Middle East" Crisis on the E&P Sector CNQ's main growth driver is the extent to which its financial results can be impacted by converting aggressive energy price increases into exceptionally high profits. Traffic restrictions through the Strait of Hormuz have led to a supply shock in the global market, resulting in a geopolitical risk premium in Brent crude oil prices rising to $30-40 per barrel. It is estimated, that global supplies of liquefied natural gas will decrease by 300 million cubic meters per day , two times more than the average volume of gas previously transported via the Nord Stream pipeline from Russia to Europe. Currently, oil and gas producers in Canada are among the most stable alternatives and "safe havens," exhibiting greater political neutrality and political st...
phuttaphat tipsana/iStock via Getty Images Highlights • U.S. investment-grade corporate bonds gained in the fourth quarter. • The fund underperformed its benchmark, the Bloomberg U.S. Corporate Bond Index. • Individual security selection detracted from performance while sector allocation and yield curve positioning were additive to performance during the quarter. Market review and outlook U.S. inv...
phuttaphat tipsana/iStock via Getty Images Highlights • U.S. investment-grade corporate bonds gained in the fourth quarter. • The fund underperformed its benchmark, the Bloomberg U.S. Corporate Bond Index. • Individual security selection detracted from performance while sector allocation and yield curve positioning were additive to performance during the quarter. Market review and outlook U.S. investment-grade corporate bonds posted positive returns in the fourth quarter, capping a solid year of performance. Despite further declines in consumer sentiment, the U.S. economy posted its fastest quarterly growth rate in two years in the third quarter, led by strong consumer spending. Nonetheless, continued weakness in the labor market, including a four-year high in the unemployment rate, led the U.S. Federal Reserve (Fed) to cut short-term interest rates twice during the quarter. The Fed's decision-making was complicated by the longest federal government shutdown in the nation's history, which caused delays and hiccups in the government's economic data collection and reporting. The yield curve steepened during the quarter as short-term bond yields declined, reflecting the Fed rate cuts, while intermediate-term bond yields were largely unchanged, and long-term bond yields rose slightly. Investment-grade corporate bonds underperformed the broader bond market during the quarter due to their greater exposure to the long end of the yield curve. The economic and political uncertainty that permeated the financial markets in 2025 is likely to remain a significant factor in the coming year. The market consensus regarding the Fed in 2026 is for two interest rate cuts, but that outlook could be impacted by both economic developments and a new Fed chair, who will be appointed when the current chair's term expires in May. Contributors and detractors The fund underperformed the benchmark in the fourth quarter, primarily due to individual security selection. Noteworthy detractors inclu...